ReviewTrends in neurosciences2015
Innate Immunity Fights Alzheimer's Disease.
Review in Trends in neurosciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- A Novel Competing Endogenous RNA Linked to Dysregulated Neuroinflammation in Alzheimer's Disease.Cells · 2026Article
- Neutrophils and aortic medial amyloid: mutually beneficial or a dangerous combination?Frontiers in immunology · 2026Article
- Unraveling the Immune Puzzle: Role of Immunomodulation in Alzheimer's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Review
- Vitamin D Reduces GABA-Positive Astrocytes in the 5xFAD Mouse Model of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2024Article
- Mutated Toll-like receptor 9 increases Alzheimer's disease risk by compromising innate immunity protection.Molecular psychiatry · 2023Article
- VEGF-A in serum protects against memory impairment in APP/PS1 transgenic mice by blocking neutrophil infiltration.Molecular psychiatry · 2023Article
- Modifiable Innate Biology within the Gut-Brain Axis for Alzheimer's Disease.Biomedicines · 2022Review
- The Role of Vitamin D in Alzheimer's Disease: A Transcriptional Regulator of Amyloidopathy and Gliopathy.Biomedicines · 2022Article
- Anti-Inflammatory Gene Therapy Improves Spatial Memory Performance in a Mouse Model of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Article
- Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer's Disease.Frontiers in aging neuroscience · 2022Review
- Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases.Molecular neurobiology · 2022Review
- Microglia-Mediated Inflammation and Neural Stem Cell Differentiation in Alzheimer's Disease: Possible Therapeutic Role of KFrontiers in cellular neuroscience · 2022Review
- Article
- Non-productive angiogenesis disassembles Aß plaque-associated blood vessels.Nature communications · 2021Article
- Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy.Molecular neurodegeneration · 2021Article
- Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition.eLife · 2021Article
- Decreased Netrin-1 in Mild Cognitive Impairment and Alzheimer's Disease Patients.Frontiers in aging neuroscience · 2021Article
- An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease.Science translational medicine · 2020Article
- Determination and Comparison of Short-Chain Fatty Acids in Serum and Colon Content Samples: Alzheimer's Disease Rat as a Case Study.Molecules (Basel, Switzerland) · 2020Article
- Microglial memory of early life stress and inflammation: Susceptibility to neurodegeneration in adulthood.Neuroscience and biobehavioral reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Alzheimer's disease (AD) is the most common age-related dementia. Pathognomonic accumulation of cerebral β-amyloid plaques likely results from imbalanced production and removal of amyloid-β (Aβ) peptides. In AD, innate immune cells lose their ability to restrict cerebral Aβ accumulation. At least in principle, mononuclear phagocytes can be enlisted to clear Aβ/β-amyloid from the brain. While the classical focus has been on dampening neuroinflammation in the context of AD, we hypothesize that rebalancing cerebral innate immunity by inhibiting actions of key anti-inflammatory cytokines returns the brain to a physiological state. Recent experiments demonstrating beneficial effects of blocking anti-inflammatory cytokine signaling in preclinical mouse models provide supportive evidence. This concept represents an important step toward innate immune-targeted therapy to combat AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.